Summit Therapeutics DMD CDI Clinical Programs 2017

Summit Therapeutics presents clinical-stage programs for Duchenne Muscular Dystrophy and C. difficile Infection. The company is advancing utrophin modulation as a universal DMD approach and microbiome-preserving treatments for CDI, leveraging a seasoned biotech team's expertise in rare and infectious disease drug development.